DelveInsight's "Bacterial Vaginosis Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the Bacterial Vaginosis, historical and forecasted epidemiology as well as the Bacterial Vaginosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Bacterial Vaginosis Market Key Facts
- As per the American Sexual Health Association 2019, BV is a common gynecologic infection, affecting nearly 29% of women in the US.
- As per the study conducted by David A. Eschenbach et al. (2007), BV is one of the most common infections among sexually active women that is responsive to antibiotics. BV is present in at least 15% of the sexually active population; this makes BV 3–4 times more common than urinary tract infections.
- The United States has the highest percentage of prevalent diagnosed and treated patients of BV among the 7MM.
Bacterial Vaginosis Market Share and Trends Analysis
The dynamics of the Bacterial Vaginosis market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world and expected the launch of emerging therapies during the study period.
The Bacterial Vaginosis market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Bacterial Vaginosis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Bacterial Vaginosis market trends and share analysis of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Bacterial Vaginosis Epidemiology Forecast
The Bacterial Vaginosis epidemiology section covers insights about historical and current Bacterial Vaginosis patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Bacterial Vaginosis Pipeline Analysis and Key Market Players
The Bacterial Vaginosis Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bacterial Vaginosis market or expected to get launched in the market during the study period. The analysis covers Bacterial Vaginosis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Some of the key player's Bacterial Vaginosis market includes:
- Dare Biosciences
- IPRAD pharma
- Osel
- Gedea Biotech
- And many others.
For more information on Bacterial Vaginosis Market, visit: https://www.delveinsight.com/report-store/bacterial-vaginosis-market